Currus Biologics
PrivateLast Round
Series A
Jun 28, 2021
Total Funding Raised
$7.6M
Company Overview
Currus Biologics operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Series A round in June 2021.
Currus Biologics is a biotechnology company developing CAR-T cell therapies utilizing its proprietary BEAT technology to treat solid tumor cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Currus Biologics Comparables
Compare Currus Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inceptor Bio | 81% | |
| Triumvira Immunologics | 78% | |
| AffyImmune Therapeutics | 78% |
For institutional investors. Book with your work email.
Currus Biologics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Currus Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Uniseed | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 7, 2025
Monthly visitors increased 90% MoM, reaching 2.1K.
- Jun 28, 2021
$8M round led by Uniseed
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- integrates_withOct 30, 2026
Currus Bio automates manufacturing of CUR-001 CAR T-cell therapy with Octane co's Cocoon(R) platform through a closed process designed to support consistent production ahead of a Phase 1 trial, announced on Oct 27th '26.
- is_developingOct 26, 2026
Currus Bio is developing BEAT, a proprietary, universal, bispecific antibody platform designed to unlock CAR T-cell therapy for solid tumours, while Currus and Octane Biotech automate manufacturing for CUR-001 on Octane's Cocoon Platform in Australia on Oct 26th '26.
- is_developingSep 28, 2026
Currus Bio is developing CAR T-cell therapy for solid tumours through its BEAT bispecific antibody platform, and FDA clearance of the CUR-001 IND enables a first-in-human Phase 1 basket trial, with the first patient expected to be dosed in early 2027.
- is_developingSep 28, 2026
Currus Bio is developing the BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) bispecific antibody platform in Australia to unlock CAR T-cell therapy for solid tumours.
For institutional investors. Book with your work email.
Currus Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Currus Biologics's valuation, stock price, and market status.
Is Currus Biologics a public or private company?
Currus Biologics is a private company.
What is the current stock price of Currus Biologics?
Currus Biologics is a private company, so its shares have no public market price. Caplight tracks Currus Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Currus Biologics worth (valuation)?
Valuation information for Currus Biologics is not publicly available.
Can I buy Currus Biologics stock?
Currus Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Currus Biologics's last funding round?
Currus Biologics's most recent funding round was Series A on June 28, 2021.
Who are the main investors in Currus Biologics?
Key investors in Currus Biologics include Uniseed.
Will Currus Biologics IPO soon?
No public IPO plans have been announced for Currus Biologics.
How can I track Currus Biologics secondary market activity?
Caplight tracks bids, offers, and trades in Currus Biologics's shares on secondary markets.